Please note that this product (marketed as Vantobra) was withdrawn from the Community Register of designated orphan medicinal products in June 2014 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 27 February 2009, orphan designation (EU/3/09/613) was granted by the European Commission to PARI Pharma GmbH , Germany, for tobramycin (inhalation use) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis.
Tobramycin (inhalation use)
|Disease / condition||
Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.